Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sample Preparation for Analysis: Advanced Techniques01:08

Sample Preparation for Analysis: Advanced Techniques

1.4K
Accurate analysis of complex samples often requires advanced preparation techniques to achieve reliable and reproducible results. Samples containing inorganic or organic materials can be challenging to dissolve or decompose effectively. Standard sample preparation methods include acid digestion, fusion, dry ashing, and wet digestion.
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
1.4K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Precipitation Titration: Endpoint Detection Methods01:19

Precipitation Titration: Endpoint Detection Methods

6.0K
In argentometric precipitation titrations, endpoints can be detected visually by the Mohr, Volhard, and Fajans methods. In the Mohr method, adding a soluble chromate indicator gives an initial yellow color to the analyte solution. As the titrant is added, the first excess of silver ions forms a red silver chromate precipitate, marking the endpoint. The solution pH should be maintained at about 8 by adding solid CaCO3.
In the Volhard method, a standard excess of AgNO3 is first added to the...
6.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

420
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
420
Clinical Trials01:16

Clinical Trials

10.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

Annals of surgery·2026
Same author

Global Consensus on the Management of Primary Localized Chordoma.

JAMA oncology·2026
Same author

Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.

European radiology experimental·2026
Same author

Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

ASO Visual Abstract: Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis using Radiomics: An International Multi-center Cohort Study.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Feb 3, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.2K

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Marion Savina1,2,3,4, Saskia Litière5, Antoine Italiano6

  • 1Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux cedex 33076, France.

Oncotarget
|October 24, 2018
PubMed
Summary

Progression-free survival (PFS), time-to-progression (TTP), and time-to-treatment failure (TTF) show weak surrogate properties for overall survival (OS) in advanced soft tissue sarcomas (STS). These endpoints are not reliable predictors of treatment efficacy in STS trials.

Keywords:
meta-analysisrandomized trialsarcomasurrogate endpointssurvival

More Related Videos

Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates
08:16

Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates

Published on: May 9, 2016

11.1K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K

Related Experiment Videos

Last Updated: Feb 3, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.2K
Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates
08:16

Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates

Published on: May 9, 2016

11.1K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K

Area of Science:

  • Oncology
  • Clinical Trials
  • Biostatistics

Background:

  • Alternative endpoints to overall survival (OS) are crucial for assessing treatment efficacy in randomized controlled trials (RCTs).
  • The validity of surrogate endpoints like progression-free survival (PFS), time-to-progression (TTP), and time-to-treatment failure (TTF) requires rigorous evaluation.
  • Advanced soft tissue sarcomas (STS) present a clinical context where reliable surrogate markers are needed.

Purpose of the Study:

  • To evaluate the surrogate properties of PFS, TTP, and TTF for OS in advanced STS.
  • To assess the individual- and trial-level associations between these candidate surrogates and OS.

Main Methods:

  • A meta-analysis of individual-patient data (IPD) was conducted.
  • Phase II/III RCTs involving adult patients with advanced STS were included.
  • Statistical methods included weighted linear regression and a two-stage model; association strength was ranked using IQWiG guidelines.

Main Results:

  • Fourteen RCTs (N=2846) were analyzed.
  • Individual-level associations were moderate, with 12-month PFS showing the highest correlation (Spearman's rho = 0.66).
  • Trial-level associations for all three endpoints were ranked as low according to IQWiG criteria.

Conclusions:

  • The findings do not support PFS, TTP, or TTF as strong surrogate endpoints for OS in advanced STS.
  • These surrogate markers may not be sufficiently reliable for assessing treatment efficacy in this patient population.